Reports Q2 revenue $0.4M vs. $0.3M last year. “The company’s transformation into a royalty-based business is ongoing. As we phase out our historical business operations, we remain focused on reducing costs and conserving cash,” stated Marlan D. Walker, CEO of TherapeuticsMD.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
